Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 761052
Company: BIOMARIN PHARM
Company: BIOMARIN PHARM
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
BRINEURA | CERLIPONASE ALFA | 30MG/ML | INJECTABLE;INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
04/27/2017 | ORIG-1 | Approval | N/A; Orphan |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/761052Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761052Orig1s000TOC.cfm |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
07/10/2024 | SUPPL-16 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761052s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761052Orig1s016ltr.pdf | |
07/24/2024 | SUPPL-14 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761052s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761052Orig1s014ltr.pdf | |
03/27/2020 | SUPPL-8 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761052s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761052Orig1s008ltr.pdf | |
12/06/2019 | SUPPL-7 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761052s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/761052Orig1s007ltr.pdf | |
12/11/2018 | SUPPL-3 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761052s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761052Orig1s003ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
07/24/2024 | SUPPL-14 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761052s014lbl.pdf | |
07/10/2024 | SUPPL-16 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761052s016lbl.pdf | |
03/27/2020 | SUPPL-8 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761052s008lbl.pdf | |
12/06/2019 | SUPPL-7 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761052s007lbl.pdf | |
12/11/2018 | SUPPL-3 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761052s003lbl.pdf | |
04/27/2017 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761052lbl.pdf |